Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.59 |
| ▸ | THRA | P10827 | 10/20 | 0.49 |
| ▸ | THRB | P10828 | 10/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | ASPH | Q12797 | 1/20 | 0.48 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.48 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886217 | 0.91 | EGLN1 (0.56) | EGLN1FTOEGLN3 | |
| SCHEMBL2882130 | 0.91 | EGLN1 (0.58) | EGLN1FTOEGLN3 | |
| SCHEMBL2883326 | 0.89 | EGLN1 (0.48) | EGLN1THRATHRBFTOEGLN3 | |
| SCHEMBL2886611 | 0.87 | EGLN1 (0.61) | EGLN1FTOEGLN3 | |
| SCHEMBL2889099 | 0.85 | EGLN1 (0.62) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL2881457 | 0.85 | EGLN1 (0.56) | EGLN1FTOBBOX1ASPHKDM8 | |
| SCHEMBL2881449 | 0.85 | EGLN1 (0.56) | EGLN1FTOEGLN2EGLN3 | |
| SCHEMBL2881294 | 0.83 | EGLN1 (0.52) | EGLN1THRATHRB | |
| SCHEMBL2881509 | 0.83 | EGLN1 (0.59) | EGLN1FTOEGLN3 | |
| SCHEMBL2883339 | 0.83 | EGLN1 (0.50) | EGLN1FTOEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | claimed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | claimed |
| US-8575239-B2 | Curing composition and cured product prepared by using the same | LG CHEM, LTD. (KR) | 2013-11-05 | — | — | US | claimed |
| EP-2195365-B1 | CURING COMPOSITION AND CURED PRODUCT PREPARED BY USING THE SAME | LG CHEMICAL LTD (KR) | 2012-11-21 | — | — | EP | claimed |
| EP-2231781-B1 | CURING COMPOSITION AND CURED PRODUCT PREPARED BY USING THE SAME | LG CHEMICAL LTD (KR) | 2012-09-26 | — | — | EP | claimed |
| JP-2010540746-A | — | — | 2010-12-24 | — | — | JP | claimed |
| US-20100286302-A1 | CURING COMPOSITION AND CURED PRODUCT PREPARED BY USING THE SAME | SHANJIN OPTOELECTRONICS (SUZHOU) CO., LTD. (CN) | 2010-11-11 | — | — | US | claimed |
| US-20100240790-A1 | CURING COMPOSITION AND CURED PRODUCT PREPARED BY USING THE SAME | LG CHEM, LTD. (KR) | 2010-09-23 | — | — | US | claimed |
| EP-2195365-A2 | CURING COMPOSITION AND CURED PRODUCT PREPARED BY USING THE SAME | LG Chem. Ltd. (KR) | 2010-06-16 | — | — | EP | claimed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | claimed |
| WO-2009045081-A2 | CURING COMPOSITION AND CURED PRODUCT PREPARED BY USING THE SAME | LG CHEM, LTD. (KR) | 2009-04-09 | — | — | WO | claimed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | claimed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | claimed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | claimed |
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885THRA 1049/4885THRB 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.